FUSION regimen: Ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 12, 2012, Pages 1737-1744

  Monés, Jordi ^a   Biarnés, Marc ^a   Trindade, Fabio ^a   Casaroli Marano, Ricardo ^b  

^a CENTRO MÉDICO TEKNON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anti VEGF therapy; Exudative age related macular degeneration; FUSION; PRN regimen; Ranibizumab; Treat and extend regimen

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE RETINA MACULA AGE RELATED DEGENERATION; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SNELLEN CHART; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84871264975     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2009-5     Document Type: Article

References (24)

1. Mitchell PR, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2-13
2. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 145:239-248
3. Monés J, for the EXCITE Study Group (2008) Safety and tolerability of two dosing regimens of ranibizumab in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration: outcomes of the EXCITE study. XXVIth Meeting of the Club Jules Gonin, St Moritz, Switzerland, 10-13 September; Poster presentation
4. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831-839
5. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
6. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663-671
7. Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G (2009) Results of oneyear's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409-413
8. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740-1747
9. Biarnés M, Monés J, Villalbí JR, Arias L (2011) As-needed treatment with ranibizumab 0.5 mg in patients with neovascular agerelated macular degeneration. Eur J Ophthalmol 21:282-289
10. Pauleikhoff D, Kirchhof B (2011) Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol 249:631-632
11. The CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
12. Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627-637
13. Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679-680
14. Spaide RF (2009) The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148:1-3
15. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134-2140
16. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26-30
17. Monés J (2011) A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. Ophthalmologica 225:112-119
18. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
19. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
20. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B (2011) Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 118:523-530
21. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850-857
22. Singer M, Wong P, Wang P-W, Scott L (2009) HORIZON extension trial of ranibizumab (Lucentis®) for neovascular age-related macular degeneration (AMD): two-year safety and efficacy results. Invest Ophthalmol Vis Sci 50: E-abstract 3093
23. Verbraak F, Schlingemann R, Mitchell P, Holz F, Inhoffen W, Weichselberger A (2009) SUSTAIN study: evaluating visual acuity recovery after a single ranibizumab re-treatment in patients with neovascular AMD. 9th EURETINA Congress, Nice, France, 14-17 May; Oral presentation
24. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S (2011) Comparing ranibizumab with bevacizumab. Ophthalmology 118:600-600.e.2